These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22711098)

  • 1. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab.
    Brizi MG; Galeazzi M; Lucherini OM; Cantarini L; Cimaz R
    Ann Intern Med; 2012 Jun; 156(12):907-8. PubMed ID: 22711098
    [No Abstract]   [Full Text] [Related]  

  • 2. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes.
    Zhuang L; Chen J; Yu J; Marathe A; Sahajwalla C; Borigini M; Maynard J; Burckart GJ; Wang Y
    Clin Pharmacol Ther; 2019 Sep; 106(3):557-567. PubMed ID: 30447083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Trap" the diagnosis: a man with recurrent episodes of febrile peritonitis, not just familial Mediterranean fever.
    Arad U; Niv E; Caspi D; Elkayam O
    Isr Med Assoc J; 2012 Apr; 14(4):229-31. PubMed ID: 22675839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of canakinumab for mosaic tumor necrosis factor receptor associated periodic syndrome.
    Terré A; Vautier M; Kahn JE; Georgin-Lavialle S; Boursier G
    Eur J Intern Med; 2024 May; 123():156-158. PubMed ID: 38307733
    [No Abstract]   [Full Text] [Related]  

  • 6. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
    La Torre F; Muratore M; Vitale A; Moramarco F; Quarta L; Cantarini L
    Rheumatol Int; 2015 Nov; 35(11):1943-7. PubMed ID: 26048626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor inhibitors in tumor necrosis factor receptor-associated periodic syndrome: still a chance to work?
    Rigante D
    Intern Emerg Med; 2017 Mar; 12(2):269-270. PubMed ID: 27817124
    [No Abstract]   [Full Text] [Related]  

  • 8. Canakinumab for the treatment of TNF-receptor associated periodic syndrome.
    La Torre F; Caparello MC; Cimaz R
    Expert Rev Clin Immunol; 2017 Jun; 13(6):513-523. PubMed ID: 28454496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.
    Cantarini L; Lopalco G; Vitale A; Caso F; Lapadula G; Iannone F; Galeazzi M; Rigante D
    Int J Rheum Dis; 2015 May; 18(4):473-5. PubMed ID: 25522898
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.
    de Koning HD; Schalkwijk J; van der Meer JW; Simon A
    J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363
    [No Abstract]   [Full Text] [Related]  

  • 11. Canakinumab in Schnitzler syndrome.
    Vanderschueren S; Knockaert D
    Semin Arthritis Rheum; 2013 Feb; 42(4):413-6. PubMed ID: 22901459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
    Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
    Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hereditary periodical fever syndromes].
    Herlin T; Sørensen N; Veirum J
    Ugeskr Laeger; 2011 Mar; 173(13):968-73. PubMed ID: 21453638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corneal response to canakinumab in cryopyrin associated periodic fever syndrome.
    Tsatsos M; Hawkin PN; Hossain P
    Br J Ophthalmol; 2013 Aug; 97(8):1081-2. PubMed ID: 23740963
    [No Abstract]   [Full Text] [Related]  

  • 15. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
    Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
    Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report.
    Ulusoy E; Karaca NE; El-Shanti H; Kilicoglu E; Aksu G; Kutukculer N
    J Med Case Rep; 2015 Jun; 9():145. PubMed ID: 26100510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.
    de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A
    Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of Schnitzler syndrome with canakinumab.
    Pesek R; Fox R
    Cutis; 2014 Sep; 94(3):E11-2. PubMed ID: 25279482
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in the diagnosis and treatment of tumor necrosis factor receptor-associated periodic syndrome.
    Aguado-Gil L; Irarrazaval-Armendáriz I; Pretel-Irazabal M
    Actas Dermosifiliogr; 2013 Sep; 104(7):617-22. PubMed ID: 23891452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Analysis of Treatment and Outcomes of NOD2-Associated Autoinflammatory Disease.
    Yao Q; Shen B
    Am J Med; 2017 Mar; 130(3):365.e13-365.e18. PubMed ID: 27984003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.